A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma
Phase of Trial: Phase III
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Napabucasin (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms BRIGHTER
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma
- 30 Sep 2019 Status changed from active, no longer recruiting to completed.
- 19 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 02 Jul 2019 This trial has been discontinued in UK.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History